Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MariMedMRMD -0.79% EV-to-EBIT is -71.42 as of Aug. 04, 2026. The stock has 5 warning signs investors should review. Among 691 Drug Manufacturers companies, MariMed ranks worse than 144717.66% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MariMed's Enterprise Value is $106.3 Mil.
MariMed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.5 Mil. Therefore, MariMed's EV-to-EBIT for today is -71.42.
The historical rank and industry rank for MariMed's EV-to-EBIT or its related term are showing as below:
MRMD'
s EV-to-EBIT Range Over the Past 10 Years
Min: -504.78 Med: 10.1 Max: 24048.49
Current: -71.42
During the past 13 years, the highest EV-to-EBIT of MariMed was 24048.49. The lowest was -504.78. And the median was 10.10.
MRMD's EV-to-EBIT is ranked worse than 100% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.68
vs MRMD: -71.42
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MariMed's Enterprise Value for the quarter that ended in Mar. 2026 was $108.9 Mil.
MariMed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed EV-to-EBIT Related Terms
MariMed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MariMed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MariMed's EV-to-EBIT falls into.
MariMed's current Enterprise Value is $106.3 Mil.
MariMed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed (MRMD) has a EV-to-EBIT of -71.42 as of Aug. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #999999 out of 691 companies in the Drug Manufacturers industry.
Is MariMed's EV-to-EBIT too high?
MariMed's current EV-to-EBIT is -71.42. Based on the distribution chart, MariMed ranks #999999 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MariMed's EV-to-EBIT compare to BTAI and RMTI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #999999 out of 691 companies for EV-to-EBIT. This places MariMed in the lower half of its industry. The industry median EV-to-EBIT is 15.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current EV-to-EBIT is -71.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.06 — trading 60.9% below its estimated fair value. The current EV-to-EBIT is -71.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MariMed (MRMD), the current EV-to-EBIT is -71.42 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 
